Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This might be a good play tomorrow...
MANCINI IMOIL AQUIRES CALA CORPORATION
ITRI, ITALY April 18, 2001 The Mancini Family today announced that a
definitive agreement has been signed that will merge Mancini I.M.O.I.L., a
private Italian Corporation, http://www.imoil.com into Cala Corporation.
(OTCBB: CCAA) Mancini I.M.O.I.L is approximately a $20 million (U.S.
dollars) industrial olive oil producing firm at the vanguard of today's technology.
Founded by Genesio Mancini, and enjoying more than 40 years of production
and sales of olive oil and vegetable oil products, the Company has its roots in
a very prestigious region of Italy. With constant attention to quality, Mancini
I.M.O.I.L. has become one of the most modern and efficient industries in the
sector, while respecting the ancient olive oil-production techniques and
traditions. The Company continues to look ahead to keep its actual
productivity up to the ever-changing needs.
Currently, Mancini Olive Oil is distributed in the United States by Manzo
Foods, Miami, Florida and sold to Romano Macaroni Grill's www.brinker.com
(NYSE:EAT) under the labeling of Genesio. In addition our olive products are
sold successfully throughout Europe.
"We are pleased to have established a presence in the United States by
acquiring Cala Corporation and look forward to expanding our sales visibility
throughout the United States, Canada and Japan," said Quirino Caparreli.
General Manager of Mancini, IMOIL.
Certain matters described herein contain forward-looking statements that are
made pursuant to the Safe Harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements involve a number of risks,
uncertainties or other factors beyond the Company's control, which could
cause actual results to differ materially from our current expectations.
Contact: Cala Corporation
Joseph Calla
408 230-0752
(IM) PN
SMTB Smithtown Bancorp Inc 02/15/2001 2-1stk 05/07/2001 04/20/2001 05/04/2001 Due bills redeemable 5/9
Bid $66.00 x Ask $71
http://quote.ragingbull.lycos.com/profile.cgi?symbol=SMTB&mode=p
I won't be buying into this just because the price is so high.. But the O/S and float are extremely low..
Good luck...
This is what a broker at E*Trade told me...
When it comes to buying into splits you can buy up until the execution date.. So say the..
Record Date is 2-1-01 Ex-Date 2-10-01 Then the record date doesn't mean anything.. You don't have to be a shareholder prior to the record date.. You can buy all the way up to the Ex-Date and the following day you should have more shares (Unless it was a reverse split) and the price will be adjusted proportionally..
Now!
The broker told me that when it comes to a cash dividend it is another whole story.. She told me that you have to be on record 3 business days prior to the "Record Date" (This is because it takes 3 business days to settle every transaction) So from what she told me today 4-18-01 would be the last day to buy in..
Now! Now! Now!
Just because she told me this does not make me believe it 100%.. I was on the phone with her for over 1/2 hr debating when you could buy into "Split" and still get the new shares.. I won!!!!!! She kept telling me that you had to be in 3 days prior to the Record date to receive the shares.. Then she kept telling me that the Record date was the Ex-date.. And she came out and told me she very knowledgeable when it came to these matters.. I was not questioning her personal wisdom.. She put me on hold for 5 mins and then came back to tell me that you could buy into a split play on the X-Date and receive the shares but when it came to "Dividends" you had to buy 3 days prior to the "Record" Date..
Now all this being said I still don't know.
This is confusing, but worth the hassle to try and find an answer. And I'm sorry if I have confused anyone more than they all ready were...
Larry
Thanks everyone, And have a good night.. I just got online and was reading some of the posts on here and BOBZ where people were thinking that this might be a possible RS.. And I almost had a heart attack..LOL
To me this was confusing because I have never seen anything like it.. I'm glad to be involved with it.
Take care
A good question Michael.. I think either way the float should remain low. Even if the 1,000,000 shares are sold.. I couldn't see why they would want to sell though.. This is a shell trading a little over a dollar and we are going to have a reverse merger with a company that wants to get on the nasdaq.. This all sounds good to me..
Thanks for the info Patsy!
Patsy, My last message wasn't directed at you. Sorry.
I think that it is cut and dry. My only worry is the price that it will trade after the merger. I will try to find out any info I can on Hemoxymed and if you are someone else can contact the company and clarify this for us that would be nice.
Thanks
OPHD I read it this way... The company sold its assets to Promega in November. Now the are disstributing a portion of that money to the shareholders before the merger. and if any money is left over then we should get another distribution.
That is correct when they say that OPHD shares will make up 6% of the total O/S when the merger takes place.. Their 19,000,000 and OPHD 1,200,000..
Where do you get that that means we'll only have 6% of our price per share? The O/S and the float are still going to be low so I would think that the price ought to go higher when they finalize the merger. IMHO
I'm out of here for today and I have to work tomorrow so good luck to all of you .. I'll chat with you on Thursday :)
Larry
With how fast BKTV fell this morning, I would have to think that it would gap back up into the .03 to .035 range by close. I thought that there were a lot of buys within this range yeaterday and not much selling this morning to drop it like they did.. JMHO
I'll be backing everyone up.. If I am not the first on the threads. Good luck everyone.
Larry
I'm ready!
Are we ready to spread the word?
I'm in! Thanks..
BTGC: Looks good maybe for a day trade.
04/16 19:46 Bio-Technology General Corp. Announces First Quarter 2001
Earnings <BTGC.O>
Bio-Technology General Corp. Announces First Quarter 2001 Earnings Results; Revenues Up 101%, Product Sales Up 139%
ISELIN, N.J.--(BUSINESS WIRE)--April 16, 2001--
Net Income $9.5 Million Vs. $1.1 Million
EPS $0.17 Vs. $0.02 (Exclusive of Certain Non-recurring Items)
Bio-Technology General Corp. (NASDAQ:BTGC) today reported pro forma income from operations of $9.5 million, or $0.17 per share, for the quarter ended March 31, 2001, compared to $1.1 million, or $0.02 per share, in the first quarter of 2000. These results are exclusive of the effect of the write-off, in accordance with generally accepted accounting principles, of purchased in-process technologies resulting from the acquisition of Myelos Corporation on March 19, 2001, and exclusive of the cumulative effect of the change in accounting principle relating to the recognition of contract fee revenues ("SAB 101"), in 2000.
Revenues and product sales for the first quarter of 2001 were approximately $34 million and $30 million, respectively, the highest such quarterly numbers recorded by the Company to date. Revenues and product sales increased 101% and 139%, respectively, from approximately $17 million and $13 million, respectively, in the first quarter of 2000. Product sales in the first quarter of 2001 accounted for 89% of revenues.
Sales of Oxandrin(R) increased 233% from $5.0 million in the first quarter of 2000 and 69% from $9.9 million in the fourth quarter of 2000 to $16.7 million in the first quarter of 2001. The increase resulted in part from sales of Oxandrin by the Ross Products Division of Abbott Laboratories in the long-term care sector, under a strategic co-marketing alliance with BTG and, in the case of the comparison with the first quarter of 2000, in part from Gentiva's completion of its inventory reduction in May 2000. Since the Ross launch of Oxandrin in late 2000, prescriptions for the product have increased dramatically. Oxandrin prescriptions in January and February 2001 were 27% higher than prescriptions in November and December 2000, and 37% higher than prescriptions in January and February 2000, respectively. Sales of the Company's human growth hormone, Delatestryl(R), and BioLon(TM) were $5.5 million, $5.3 million, and $2.2 million, compared to $4.0 million, $1.6 million, and $1.8 million, respectively, in the first quarter of 2000. BTG's sales of Delatestryl to Gentiva in 2000 were affected by a reduction of inventory by Gentiva in anticipation of the reintroduction of a competitor's product that did not materialize.
Pro forma expenses for the first quarter of 2001 were $19.8 million compared to $15.1 million in the first quarter of 2000. The increase in expenses was primarily due to a significant increase in the cost of product sales mainly as a result of the increase in product sales, and a substantial increase in marketing and sales expenses connected with the marketing of Oxandrin.
For the quarter ended March 31, 2001, including the effect of the write-off, in accordance with generally accepted accounting principles, of purchased in-process technologies resulting from the acquisition of Myelos, the Company recorded a net loss of $36.1 million, or $0.66 per share. In the comparable quarter of 2000, including the effect of SAB 101, the Company had a net loss of $7.1 million, or $0.12 per share.
Commenting on the results, Sim Fass, Chairman and CEO stated: "We are highly encouraged by the marked increase in product sales in the first quarter of 2001, and in particular by the significant growth in Oxandrin prescriptions. Most of the increase is attributed to the initial impact of our co-marketing alliance with Abbott. As a result of that alliance, approximately one-third of all Oxandrin prescriptions is currently being generated in the long-term care sector. Oxandrin is reaching many more individuals with involuntary weight loss and is beginning to achieve the broader market penetration we anticipated. We look forward to seeing additional growth in Oxandrin sales as the co-marketing alliance takes full effect. Given our robust earnings this quarter, we believe that our EPS growth target of twenty-five to thirty percent for 2001, exclusive of certain non-recurring items, is achievable and may well be exceeded."
First Quarter Developments
-- On March 19, BTG completed the acquisition of Myelos
Corporation, a privately held biopharmaceutical company
focused on the development of novel therapeutics to treat
diseases of the nervous system.
Myelos' technology platform enables the isolation of stimulatory peptides (short chains of amino acids) derived from growth factors. This has led to the development of Prosaptide(TM), a promising new compound for the treatment of neuropathic pain associated with diabetic peripheral neuropathy. A Phase II human clinical trial in Type I and Type II diabetes mellitus completed by Myelos demonstrated that Prosaptide effectively decreases pain associated with diabetic peripheral neuropathy without deleterious side effects.
Diabetic peripheral neuropathy is a serious and debilitating complication of Type I and Type II diabetes mellitus that usually affects the feet and legs. Symptoms include pain, numbness, and tingling. An estimated 8.8 million diabetics have peripheral neuropathy, while approximately 2.6 million of them have been diagnosed and are symptomatic. Due to the fact that available treatment options for pain associated with diabetic peripheral neuropathy are often unsatisfactory and frequently accompanied by unacceptable side effects, only approximately one-third of patients who are diagnosed and symptomatic are currently treated. BTG believes that the annual worldwide market potential for Prosaptide in the treatment of diabetic neuropathic pain may be in excess of $800 million.
Under the terms of the acquisition, BTG paid Myelos stockholders approximately $35 million in a combination of cash and stock (approximately $14 million in cash and $21 million in equity (approximately 2.3 million shares of common stock)). Despite this increase in shares, BTG anticipates being able to achieve pro forma EPS growth in 2001 over 2000. The shares issued to Myelos are unregistered. Although BTG has agreed to register them under the Securities Act, the principal stockholders of Myelos have agreed to limit their sale of BTG shares in any three-month period. This lockup agreement expires after two years.
An additional future payment of $30 million in a combination of cash and stock is contingent upon BTG being in position to file a New Drug Application for FDA approval of Prosaptide in the treatment of neuropathic pain. A final payment of 15% of worldwide net sales in the third year of commercialization will be made in a combination of cash and stock.
-- In January 2001, The Ferring Group, BTG's licensee for Europe, received approval from the European Regulatory authorities for
BTG's recombinant human growth hormone, in the treatment of
Turner's syndrome. Turner's syndrome is a genetic disorder in
girls that occurs in approximately 1 in 2,500 live births and
results in short stature and failure to develop secondary
sexual characteristics. Human growth hormone is effective in
promoting growth and improving final height in girls with this
condition. Anticipated Developments in 2001
-- Continuing growth in Oxandrin prescriptions and sales via the
co-marketing relationship with Abbott
-- Launch of BioHy(TM) in Europe by DePuy Orthopaedics, a Johnson
& Johnson company
-- Additional launches of Silkis(R) in Europe and Latin America
by Galderma
-- Approval and launch of recombinant human insulin in Poland and
Eastern Europe by Ibatech
-- Completion of Phase III clinical trial of Fibrimage(TM) by
Draxis in the detection of deep vein thrombosis
-- Initiation of Phase I clinical trial of Puricase(TM) in
gout/hyperuricemia
-- Initiation of Phase IIb clinical trial of OxSODrol(TM) in the
prevention of reactive airway disease in premature neonates
-- Completion of protocol design for Phase IIb clinical trial of
Prosaptide in the prevention of pain associated with diabetic
peripheral neuropathy
-- Completion of pre-clinical development of anti-leukemia agent
Bio-Technology General Corp., a leading biopharmaceutical company, develops, manufactures and markets genetically engineered and other products for human health care. BTG's products are marketed worldwide. Products sold in the United States are Oxandrin(R) (oxandrolone, USP), marketed by BTG and by the Ross Products Division of Abbott Laboratories under a co-promotion agreement, Delatestryl(R) (testosterone enanthate), marketed by BTG, Mircette(TM) (oral contraceptive), marketed by Organon, Inc., and BioLon(TM) (sodium hyaluronate), marketed by Akorn, Inc. Products sold internationally
© Copyright 2001 Reuters. Click Here for Limitations and Restrictions on Use.
I mentioned IMON the other day. They have news out on their website tonight.. Might be good play?
Larry
Hi, I also get sick of seeing the Phantom's posts.. I actually try and stay away from stocks that he is in.. (Most of the time)
I see that pennybuster is going to pick TELI as his new pick..
I wonder if BKTV has anything left in it. I will be watching it tomorrow. I had an order in for .02 that filled for me today. So I am happy to see that it is up from my purchasing price.
And I would also like to see some good news or a sec filing on RNWR.
Take care
Larry
Hello all, I have to work on Monday. Let's hope that this week will be at least as good as last week.
I noticed that IMON was up 100% on Thurday. Might be one to look at also.. The float is 32 mil.. Don't know why the jump.
Also AASI might be a good one long term...
Have a good day everyone.
Larry
You guys have a nice weekend.. I hope DCTG does well for us next week.. I was able to buy 25,000 at .049 before they up ticked the ask. Then I had a purchase order in for 16,000 at .052.. They didn't fill.
Take care
Larry
Thanks, I was going to ask if it was a prior split. I thought that it was.
Is this correct? Bid 0.0470 - Ask 0.0570 for DCTG
Thanks for the responses guys. Sorry, I did mean 2 mil. I don't know what the average daily volume has been over the past few weeks but I don't think that it has been this high. RB board has been quiet also. And it doesn't appear that there will be much profit taking since news is pending and the lowest you might have been able to get in was around .03. Also, is the float estimate right at around 15 mil?
Michael/Shac, Any price expectations on DCTG? I see that it has over 200mil shares traded today. TIA
Larry
Michael, I couldn't find O/S or float on TWEB. I also have read on RB that QKKA will have a meeting tomorrow about a possible 50:1 Reverse split... And CONV is now .15 x .16.. I am not in any of these.
Looks like you and shac have been doing well lately.. Glad to hear.. Keep it up..
I bought IFCI today.. It is green for me.. And right now that is good for me.. RNWR spread has been outrageous.. Still holding 10,000 shares incase it does split.. And I finally received my GPRX shares tonight.. I will exit GPRX in the morning..
Seems like a lot of the stocks are starting to respond positively.
Larry
20/20 Web Design Inc. Announces the Execution of a Definitive Agreement for Its Merger with BentleyTel.com Inc.
20/20 Web Design, Inc. Will File for a Name Change To BentleyTel.com Inc.
WOODLAND HILLS, Calif., April 10 /PRNewswire/ -- 20/20 Web Design, Inc. (OTC Bulletin Board: TWEB - news) announced that it has executed a definitive agreement, accounted for as an acquisition, to acquire Newport Beach based Smart-e-Card developer BentleyTel.com Inc. www.bentleytel.com
20/20 Web Design, Inc.'s management has approved a 4-1 forward split of its common stock with a record date of April 16, 2001. The Company has also filed to change its OTCBB trading symbol and the Company's name to BentleyTel.com Inc.
The Company announced that Mr. Irving Einhorn, former Regional Administrator for the Los Angeles Securities & Exchange Commission, has accepted the position of Chairman of the Board of BentleyTel. Mr. Einhorn is presently an attorney in private practice and the Company is privileged to have him as chairman. The Company is seeking to expand its board further and has had positive indications for board positions from its strategic partners and other related technology companies.
BentleyTel's Snap & Send Card, to be released this month, is the first of in a series of innovative international re-chargeable card products that will be released by the Company.
The BentleyTel Snap & Send card is also being marketed as an entry-level to first time ``plastic users.'' The marketing plan calls for an automatic upgrade to a BentleyTel Smart-e-Card after 10 recharges. The Smart-e-Card carries the same international phone platform but is also a stored value/ATM and international e-funds transfer card. (www.smart-e-card.net)
The BentleyTel products are designed to connect family members around the world and corporate travelers to their respective offices and homes via a range of phone, financial services and global unified messaging services. Management is scheduled to proceed to Australia, Malaysia and Philippines to visit its new subsidiaries and to meet the BentleyTel management in each country.
BentleyTel is currently operating as a subsidiary of Global TeleMedia International (OTC Bulletin Board: GLTI - news), though Global must satisfy pre- existing conditions, a legacy of previous management, in order to satisfy the escrow provisions in order to complete its control of BentleyTel.
Information : Contact 949-253-9588
BentleyTel.com, (www.bentleytel.com) is a leading developer of Smart-e- Cards www.smart-e-card.net interactive software for complex E-commerce solutions, Voice over IP, LAN VPN (Virtual Private Network), ISP, Virtual ISP, The Company also owns telecom, ISP, and software development facilities in the USA, Australia, Malaysia and the Philippines.
This press release contains forward-looking statements. All such statements involve risks and uncertainties, including, without limitation, the risks detailed in BentleyTel.com, Inc. and Global Telemedia's filings and reports with the Securities and Exchange Commission. Such statements are only predictions and actual events or results may differ materially.
SOURCE: BentleyTel.com Inc.
Have a good day all.. I will be gone the rest of the day.. I will chat with you tomorrow.
Larry
Thanks Michael, I never like using someone's given name on these boards unless told too. Just in case posters want to keep their identity secret.. But I agree this is a nice, close bunch...
Thanks again
Larry
BBstock, Here is the link.
http://www.bobz.com/hotstocktips/hotstocktips.html
Good Morning.. I bought IFCI on contract news.. Having no problems getting on BOBZ
Larry
BBstock I hadn't seen that PR on CTLE.. I'm not going to touch this one.. I think that it has been around a month since we noticed this possible split and the stock just didn't react at all to it..
Yeah, They dropped down to sell my shares at .09.. Now it is rebounding.. My luck I guess...
I've been trying to sell out of NHTC for the past 10 minutes.. Thet keep bypassing my sell orders.. I've had to change it at least 8 times so far:(
NHTC I'm even at the moment.. I almost bought COMM at .25 yesterday...
I don't think that you missed anything Patsy.. I sold out of UTDT at .025 yesterday and it has ran all the way up to .07..
:(
NHTC Up More... Bid 0.1190 Ask 0.1200
NHTC Upticking even more... Bid 0.1175 Ask 0.1180
BBstock, NHTC has all ready gapped up .02...
Bid 0.1150 Ask 0.1170
COOL!
Good Morning All...eom
DMNX?????????????
By: rjtow
Reply To: None Monday, 9 Apr 2001 at 11:25 PM EDT
Post # of 9973
< Previous Respond Next >
FROM YAHOO: DMNX. He told me they will postpone the 10-1 split due to
current market conditions, and also said they had a problem with one of the majority holders
"HomeWork911", was not agreeable to the split at this time. This news will be released today
or tomorrow according to him. Im sure he did not want me to post this to the board, but I felt
that our members should be aware of this possible bad news and the possible negative effect
it may have to the price.